For colon cancer, liquid biopsies were able to detect ERBB2 alterations in circulating tumor DNA (ctDNA) that were confirmed in tissue samples, suggesting that HER2 has potential as a plasma biomarker. This evidence concerns the gene ERBB2 and neoplasm.